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Summary The aim of the study was to determine whether past exposure to hepatitis B virus (HBV) influences the risk of the development of
hepatocellularcarcinoma (HCC) in Japanese patients with chronic liverdisease (CLD). Weconducted a hospital-based case-control studyof 141
HCC patients with CLD and 151 controls with CLD butwithout HCC. Past exposure to HBV was assessed by antibody to hepatitis B core antigen
(anti-HBc) positivity. Ninety-two patients (65%) with HCC were anti-HBc positive compared with 65 patients (43%) with CLD alone (P< 0.01). A
multivariate analysis using logistic regression modelling revealed that anti-HBc positivity significantly increased the rsk of the development of
HCC [odds ratio (OR) 2.0, P= 0.01]. In the anti-HBc-positive patients, asignificantly increased risk of HCC was seen among the patients positive
for anti-HBc alone (OR, 2.6; P< 0.01). However, a significant OR was not obtained among the patients with a transient HBV infection implied by
positivity for both antibody to hepatitis B surface antigen and anti-HBc (OR, 1.5; P= 0.48). These results indicate that past exposure to HBV is a
risk factor for HCC in Japanese CLD patients, especially when they have no serological evidence of immunity to HBV.
Keywords: hepatocellular carcinoma; chronic liver disease; hepatitis B virus; hepatitis C virus; case-control study
In Japan, the vast majority of patients with hepatocellular carci-
noma (HCC) have chronic liver disease (CLD) such as chronic
hepatitis and liver cirrhosis, and CLD patients frequently develop
HCC during the follow-up period; patients with CLD are at
increased risk of developing HCC (Ikeda et al, 1993; Tsukuma et
al, 1993). Many CLD patients are, therefore, followed up periodi-
cally using ultrasonography (US) and serum a-fetoprotein (AFP)
measurements to detectHCC at an early stage (Tanakaet al, 1990).
Evaluation ofthe risk factors for HCC in CLD patients is impera-
tive. Identification of the individuals who are at higher risk of
HCC would contribute to the early diagnosis ofthis disease and to
effective implementation ofstrategies for chemoprevention.
Numerous epidemiological and biological studies have indi-
cated that a chronic infection with hepatitis B virus (HBV) and/or
hepatitis C virus (HCV) plays an important role in hepatocarcino-
genesis (Bruix et al, 1989; Saito et al, 1990; Kim et al, 1991). As
for HBV, serum hepatitis B surface antigen (HBsAg) positivity,
which indicates a chronic HBV carrier state, is a well-established
risk factor for HCC (Beasley et al, 1981; Chen et al, 1991).
However, only a few reports have addressed the relationship
between past exposure to HBV and HCC and, as yet, no definite
conclusion has been established (Chiba et al, 1996; Yu et al, 1997).
This hospital-based case-control study was conducted to eval-
uate whether past exposure to HBV, which was assessed by anti-
body to hepatitis B core antigen (anti-HBc) positivity, influenced
the risk ofdeveloping HCC in Japanese CLD patients.
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PATIENTS AND METHODS
Study population
The HCC patient group comprised 141 consecutive patients with
HCC and underlying CLD who were referred to the National
Cancer Center Hospital, Tokyo, Japan, between January 1992 and
December 1993. This group included 110 men and 31 women who
had a mean age of 61.4 (range 25-81) years. The diagnosis of
HCC was made by histological examination in 123 patients. In the
remaining 18 patients, it was based on markedly elevated serum
AFP levels (2 400 ng ml-') with space-occupying lesions demon-
strable by various imaging studies, or on typical computerizd
tomographic (CT) and/or angiographic findings.
The CLD control group comprised 151 patients with CLD but
without evidence of HCC [96 men and 55 women, mean age 55.9
(range 25-79) years]. The CLD group consisted of consecutive
referals during the same period as the HCC patients and the
coexistence of HCC was ruled out by diagnostic methods such
as US, CT and serum AFP measurements. In both groups, the
diagnosis of CLD was based on biochemical evidence of liver
parenchymal dysfunction and clinical features such as
oesophage,al varix and splenomegaly and, whenever possible, on
histological examination (137 patients). Patients with specific
types of CLD such as autoimmune hepatitis, primary and
secondary biliary cirrhosis, and with CLD due to parasitosis,
congestive heart failure or metabolic disorders were excluded
because these CLDs appeared to differ substantially from the most
common type ofCLD observed in Japan.
Laboratory studies
Blood specimens from all patients were processed shortly after
collection and stored at - 70°C until analysis. All serum samples,
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Table 1 Distributions of age, gender, HBV markers, anti-HCV, history of
blood transfusion and alcohol abuse in HCC patients and CLD patients
Variable No. of patients(%) Odds P-value
ratio
HCC CLD (95% Cl)
patients patients
(n = 141) (n = 151)
Age
< 60 years 54 (38) 87 (58) 1.0 < 0.01
.60 years 87 (62) 64 (42) 2.2 (1.3-3.6)
Gender
Female 31 (22) 55 (36) 1.0 0.01
Male 110 (78) 96 (64) 2.0 (1.2-3.5)
HBsAg
No 118 (84) 138 (91) 1.0 0.07
Yes 23 (16) 13 (9) 2.1 (1.0-4.5)
Anti-HBs
No 125 (89) 131 (87) 1.0 0.75
Yes 16 (11) 20 (13) 0.8 (0.4-1.8)
Anti-HBc
No 49 (35) 86 (57) 1.0 < 0.01
Yes 92 (65) 65 (43) 2.5 (1.5-4.1)
Anti-HCV
No 28 (20) 44 (29) 1.0 0.09
Yes 113 (80) 107 (71) 1.7 (0.9-3.0)
History of blood
transfusion
No 86 (63) 82 (56) 1.0 0.25
Yes 50 (37) 65 (44) 0.7 (0.4-1.2)
Alcohol abusea
No 93 (67) 105 (69) 1.0 0.72
Yes 46 (33) 46 (31) 1.1 (0.7-1.9)
aEthanol intake .80 g day-' for .5 years
which were coded without regard to case or control status, were
tested for HBsAg, antibody to HBsAg (anti-HBs), anti-HBc and
antibody to HCV (anti-HCV). HBsAg was detected by reverse
passive haemagglutination. Anti-HBs was measured by passive
haemagglutination. Anti-HBc was evaluated by an enzyme
immunoassay (EIA). Titres for anti-HBc showing more than 70%
inhibition were assessed as positive, and these positive samples
werefurthertested at 1:200dilution. Thedetermination ofanti-HCV
in serum samples was made using a second-generation EIA test.
Statistical methods
The risk of developing HCC, related to each study variable, was
evaluated by calculating the odds ratio (OR) with 95% confidence
intervals (CI). A multivariate analysis was also performed by
modelling the data through unconditional logistic regression for
controlling possible confounding factors. Variables included in the
model were age, gender, HBV markers (HBsAg, anti-HBs and anti-
HBc), anti-HCV status, history of blood transfusion and alcohol
abuse (ethanol intake .80 g day-' for .5 years). Adjusted ORs and
95% CI were derived from logistic regression coefficients.
Among the anti-HBc-positive patients, the ORs were calculated
for subgroups of patients, defined by HBV markers, by using
patients without any HBV markers as reference. In each subgroup,
the proportion ofpatients showing a high inhibition rate (2 90%) at
a 1: 200 serum dilution in the anti-HBc assay was also examined.
Table 2 Distrbutions of age, gender, HBV markers, anti-HCV, history of
blood transfusion and alcohol abuse in HBsAg-negative patients




(n= 118) (n= 138)
Age
< 60 years 37 (31) 75 (54) 1.0 < 0.01
. 60 years 81 (69) 63 (46) 2.6 (1.5-4.5)
Gender
Female 25 (21) 51 (37) 1.0 <0.01
Male 93 (79) 87 (63) 2.8 (1.2-4.0)
Anti-HBs
No 103 (87) 118 (85) 1.0 0.82
Yes 15 (13) 20 (15) 0.9 (0.4-1.9)
Anti-HBc
No 49 (41) 86 (62) 1.0 < 0.01
Yes 69 (59) 52 (38) 2.3 (1.4-4.0)
Anti-HCV
No 9 (8) 34 (25) 1.0 < 0.01
Yes 109 (92) 104 (75) 4.0 (1.7-9.4)
History of blood
transfusion
No 70 (62) 73 (54) 1.0 0.29
Yes 43 (38) 61 (46) 0.7 (0.4-1.3)
Alcohol abusea
No 76 (65) 96 (70) 1.0 0.58
Yes 40 (35) 42 (30) 1.2 (0.7-2.1)
aEthanol intake > 80 g day-' for > 5 years
Statistical analyses were performed using PC-SAS, version
6.09. Significance was defined as a P-value < 0.05. All P-values
quoted are two-sided.
RESULTS
HBsAg was detected in 23 ofthe 141 HCC patients (16%) and 13
ofthe 151 CLD patients (9%) (P = 0.07); anti-HCV seropositivity
was 80% and 71% in these two groups respectively (P = 0.09;
Table 1). Concomitant chronic infection of HBV and HCV, indi-
cated by the presence of both HBsAg and anti-HCV, was seen in
four patients (3%) with HCC and three (2%) with CLD alone.
Anti-HBc was positive in 92 HCC patients (65%) and 65 CLD
patients (43%) (P < 0.01). Although the prevalence of anti-HBs
was similar between the HCC and CLD groups (P = 0.75), most
patients who were positive for anti-HBs were also positive for
anti-HBc; only three HCC patients and six CLD patients were
positive for anti-HBs alone. The univariate analysis revealed that
the risk of HCC was strongly associated with age greater than 60
years (OR 2.2, P < 0.01), male gender(OR 2.0, P =0.01) and anti-
HBc positivity (OR 2.5, P < 0.01). The anti-HBs positivity, history
of blood transfusion and alcohol abuse were not significantly
different between the CLD patients with or without HCC.
Table 2 presents the distributions ofthe variables described above
in the HBsAg-negative patients (118 HCC patients and 138 CLD
patients). The prevalence of anti-HCV and anti-HBc was high in
both the HCC patients and CLD patients; however, the prevalence
of anti-HCV and anti-HBc was significantly higher in the HCC
patients compared with patients who had CLD alone. Anti-HCV
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Table 3 Risk factors for HCC in CLD patients calculated by logistic
regression analysis
Variable Odds ratio P-value
(95% Cl)
Advancing age (by 10 years) 1.9 (1.4-2.5) < 0.01
Male gender 2.0 (1.1-3.5) 0.02
HBsAg positivity 4.7 (1.7-12.7) < 0.01
Anti-HBc positivity 2.0 (1.2-3.5) 0.01
Anti-HCV positivity 2.3 (1.1-4.9) 0.03
was detected in 109 HCC patients (92%) and in 104 CLD patients
(75%) (OR 4.0, P < 0.01). Anti-HBc was detected in 69 HCC
patients (59%) and in 52 CLD patients (38%) (OR 2.3, P < 0.01). In
addition, significant ORs were obtained forage greaterthan 60 years
(OR 2.6, P < 0.01) and male gender (OR 2.8, P < 0.01).
The results of the multivariate unconditional logistic regression
analysis ofrisk factors are shown in Table 3. Advancing age by 10
years (OR 1.9, P < 0.01), male gender (OR 2.0, P = 0.02), HBsAg
positivity (OR 4.7, P < 0.01), anti-HBc positivity (OR 2.0,
P = 0.01) and anti-HCV positivity (OR 2.3, P = 0.03) were signif-
icantly related to the development of HCC. Anti-HBs positivity,
history of blood transfusion and alcohol abuse were not found to
be significantly associated with HCC and we did not, therefore,
include them in the final model.
Table 4 presents the distribution of the patients defined by HBV
markers in the anti-HBc-positive patients (92 HCC patients and 65
CLD patients). Anti-HBc positivity occurred in conjunction with
three patterns ofHBV markers: (1) with HBsAg indicating apersis-
tent HBV infection (36 patients), (2) with anti-HBs indicating a
resolved HBV infection (26 patients) and (3) without either ofthese
two markers (95 patients). Anti-HBc was present in all 36 HBsAg
positive patients, and among them, 30 (83%) demonstrated a high
inhibition rate (. 90%) at a 1:200 serum dilution. However, all but
two ofthe 121 HBsAg-negative patients who werepositive foranti-
HBc revealed a low inhibition rate (< 90%), indicating a previous
transient HBV infection. The significantly increased risk of HCC
was seen only among the patients positive for anti-HBc alone
(OR 2.6, P < 0.01), and not among the patients positive for both
anti-HBs and anti-HBc (OR 1.5, P = 0.48).
DISCUSSION
Abundant evidence exists in support of the contribution of chronic
HBV infection to HCC development. However, an aetiological role
of transient HBV infection in hepatocarcinogenesis remains to be
elucidated (Beasley et al, 1981; Chen et al, 1991; Ikeda et al, 1993;
Tsukuma et al, 1993). In this study, we performed a case-control
investigation of Japanese CLD patients to assess the influence of
past exposure to HBV in the development ofHCC. Past exposure to
HBV was assessed by anti-HBc positivity, since anti-HBc is the
most sensitive test available to detect a history ofHBV infection.
We found that anti-HBc was more prevalent among the CLD
patients with HCC compared with the CLD patients without HCC.
Among only the HBsAg-negative patients, we also found a signif-
icantly higher prevalence of anti-HBc in the HCC patients. The
multivariate analysis showed the same result regarding the role of
anti-HBc as a risk factor for developing HCC. Moreover, in the
anti-HBc-positive patients, the increased risk of HCC was seen
among the patients positive for anti-HBc alone. All but two of the
95 patients positive for anti-HBc alone demonstrated a low inhibi-
tion rate at a 1:200 serumdilution, supporting the involvement ofa
previous transient HBV infection in the aetiology of HCC with
CLD. However, the risk of HCC among the patients with a
resolved HBV infection indicated by positivity for both anti-HBs
and anti-HBc was not significantly enclosed. Anti-HBc positivity
had never been shown to be an independent risk factor for HCC
among CLD patients, although a significant relationship between
HBV antibodies positivity and HCC has been reported both in the
case-control study of HCC patients and control subjects without
CLD (Yu et al, 1997) and in patients with HCV-related liver
cirrhosis (Chiba et al, 1996).
The mechanism by which anti-HBc positivity is related to HCC
remains to be elucidated, although a possible involvement ofHBV
in the carcinogenesis has been pointed out in HCC patients posi-
tive for anti-HBc (Maupas et al, 1975). There are at least two
possible explanations for the close relationship between anti-HBc
positivity and HCC:
(1) HBV can cause HCC by transient infection, even ifthe
patients were not known to have chronic HBV infection.
HBV-DNA may have been inserted into cellular DNA at an
earlier stage, when the X gene or a truncated preS/S gene may
have been responsible for initiating tumorigenesis (Galloway
and McDougall, 1983; Kim et al, 1991).
(2) Chronic HBV infection cannot be excluded in HBsAg-
negative patients positive for anti-HBc, because it has been
reported that HBV-DNA can be detected in their liver tissue
and serum (Galloway and McDougall, 1983; Brechot et al,
1985; Paterlini et al, 1990; Sheu et al, 1992). Further studies
focusing on the analysis ofHBV-DNA in the liver and serum
are needed to clarify this point.
Table 4 Distribution of the patients defined by HBV markers in the anti-HBC-positive patients
(HBsAg/anti- No. of patients High Odds ratio P-value
HBs/anti-HBc) inhibition rate (95% Cl)
HCC CLD Total
patients patients
(+/-/+) 23b 13 36 30 (83%) 3.1 (1.3-7.2) < 0.01
(-/+t+) 12 14 26 0 (0%) 1.5 (0.6-3.8) 0.48
(-/-/+) 57 38 95 2 (2%) 2.6 (1.5-4.7) < 0.01
46 80 126 - 1.0- -
aMore than or equal to 90% at a 1:200 serum dilution in the anti-HBc assay; bOne patient was positive for both HBsAg and anti-HBs.
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In conclusion, a significant relationship between anti-HBc
status and HCC was revealed in the Japanese CLD patients.
Therefore, the determination of anti-HBc status might contribute
to the identification of patients at higher risk for HCC, and to
the optimization of the timing and frequency of follow-up
programmes. CLD patients positive for anti-HBc (irrespective of
HBsAg status) should be followed more closely for the early
detection of HCC, especially when they have no serological
evidence of immunity to HBV. However, long-term follow-up
studies of CLD patients should provide additional evidence
helpful in defining more precisely and directly the magnitude of
HCC risk associated with anti-HBc. Further studies are also
mandatory to establish whether our findings are consistent with
other geographical areas where the distribution ofHBV and HCV
is substantially different.
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